Global Recombinant Therapeutic Antibodies and Proteins Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Therapeutic Antibodies and Proteins Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.
Due to the COVID-19 pandemic, the global Recombinant Therapeutic Antibodies and Proteins market size was US$ 89490 million in 2022 and is forecast to a readjusted size of US$ 143680 million by 2034 with a CAGR of 6.9% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Plasma Protein accounting for % of the Recombinant Therapeutic Antibodies and Proteins global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Oncology segment is altered to an % CAGR throughout this forecast period.
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Recombinant Therapeutic Antibodies and Proteins market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Recombinant Therapeutic Antibodies and Proteins market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Recombinant Therapeutic Antibodies and Proteins market. Readers of the report can become informed about current and future trends of the global Recombinant Therapeutic Antibodies and Proteins market and how they will impact market growth during the forecast period.
Abbott
Amgen
Biogen
Eli Lilly
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
Sanofi
Segment by Type
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Recombinant Therapeutic Antibodies and Proteins in global and regional level.
Chapter 3Detailed analysis of Recombinant Therapeutic Antibodies and Proteins companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Therapeutic Antibodies and Proteins revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Due to the COVID-19 pandemic, the global Recombinant Therapeutic Antibodies and Proteins market size was US$ 89490 million in 2022 and is forecast to a readjusted size of US$ 143680 million by 2034 with a CAGR of 6.9% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Plasma Protein accounting for % of the Recombinant Therapeutic Antibodies and Proteins global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Oncology segment is altered to an % CAGR throughout this forecast period.
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Recombinant Therapeutic Antibodies and Proteins market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Recombinant Therapeutic Antibodies and Proteins market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Recombinant Therapeutic Antibodies and Proteins market. Readers of the report can become informed about current and future trends of the global Recombinant Therapeutic Antibodies and Proteins market and how they will impact market growth during the forecast period.
By Company
Abbott
Amgen
Biogen
Eli Lilly
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
Sanofi
Segment by Type
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others
Segment by Application
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Recombinant Therapeutic Antibodies and Proteins in global and regional level.
Chapter 3Detailed analysis of Recombinant Therapeutic Antibodies and Proteins companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Therapeutic Antibodies and Proteins revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices